

Description

The CBL-B-driven SRC Ubiquitination Intrachain TR-FRET Assay Kit is a sensitive high-throughput screening (HTS) TR-FRET (Time Resolved Fluorescence Resonance Energy Transfer) assay kit designed to measure the E3 ligase activity of CBL-B (Casitas B-lineage lymphoma proto-oncogene-b) toward tyrosine kinase SRC in a homogeneous 384 reaction format. It utilizes a Europium cryptate-labeled Ubiquitin Donor and a Cy5-labeled Ubiquitin Acceptor to complete the TR-FRET pairing. Since both the TR-FRET donor and acceptor are incorporated into poly-ubiquitin chains, this assay does not detect mono-ubiquitination. The FRET-based format requires no time-consuming washing steps, making it especially suitable for HTS applications as well as real-time analyses of polyubiquitination.




Figure 1: CBL-B-Driven SRC Ubiquitination Intrachain TR-FRET Assay Kit schematic.

Background

Covalent conjugation to ubiquitin (Ub) regulates protein stability, function, and localization. Ubiquitination is the concerted action of three enzymes: a Ub-activating enzyme E1, a Ub-conjugating enzyme E2, and a Ub ligase E3. The specificity and efficiency of ubiquitination are largely determined by the E3 enzyme, which directs the last step of the Ub-conjugating cascade by binding to both an E2~Ub conjugate and a substrate protein.

Casitas B-lineage lymphoma proto-oncogene-b (CBL-B) is the RING-type E3 ligase that functions as a negative regulator of T cell activation. It contains an N-terminal tyrosine kinase binding domain, a SRC homology domain, and the RING domain responsible for its catalytic function. Additionally, CBL-B contains proline-rich regions mediating the association with phosphorylated proteins, and a dimerization domain. CBL-B interacts with a large number of target proteins implicated in the control of cell proliferation, differentiation, and cell morphology. The ubiquitin ligase activity of CBL-B is up-regulated by the phosphorylation of Tyrosine 363, which opens CBL-B from its auto-inhibitory conformation, allowing binding of E2 and substrates. Kinases that phosphorylate CBL-B, such as AXL, Tyro3, and SRC, also serve as substrates for ubiquitination.

Applications

- Screen inhibitors of CBL-B Ubiquitin ligase activity in drug discovery and HTS applications.
- Determine compound IC_{50} .
- Perform real-time kinetic analyses.

Supplied Materials

Catalog #	Name	Amount	Storage
80301	UBE1 (UBA1), FLAG-Tag *	40 µg	-80°C
80314	UcbH5b, His-Tag*	60 µg	-80°C
80415	CBL-B, GST-Tag*	8 µg	-80°C
40484	SRC, His-Tag*	12 µg	-80°C
78307	TRF Ubiquitin Mix (200x)	40 µl	-80°C
	ATP (4 mM)	2 x 1 ml	-80°C
	U2 Assay Buffer	2 x 10 ml	-80°C
79969	White, nonbinding, low volume 384-well microtiter plate		Room Temp

*The initial concentration of enzyme is lot-specific and will be indicated on the tube containing the protein.

The Ubiquitin Mix is sourced from South Bay Bio LLC.

Materials Required but Not Supplied

- Fluorescent microplate reader capable of measuring Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET)
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform

Storage Conditions

This assay kit will perform optimally for up to **6 months** from date of receipt when the materials are stored as directed. **Avoid multiple freeze/thaw cycles!**

Safety

This product is for research purposes only and not for human or therapeutic use. This product should be considered hazardous and is harmful by inhalation, in contact with skin, eyes, clothing, and if swallowed. If contact occurs, wash thoroughly.

Contraindications

The CBL-B-driven SRC Ubiquitination Intrachain TR-FRET Assay Kit is compatible with up to 1% final DMSO concentration. We recommend preparing the inhibitor in a solution containing no higher than 5% DMSO and using 4 µl per well.

SRC kinase inhibitors may inhibit the ubiquitination reaction. It is recommended to confirm if the test compounds explicitly affect CBL-B ligase activity and not SRC kinase activity by determining the effect of compounds on SRC activity by using the SRC Assay Kit (BPS Bioscience #79680).

Assay Protocol

- All samples and controls should be performed in triplicate.
 - The assay should include “Blank”, “Positive control”, “Negative control” and “Test Inhibitor” conditions.
 - If the assay plate is going to be used more than once, prepare enough of each protein and aliquot the remaining undiluted proteins into single-use aliquots depending on how many times the assay plate will be used. Store the protein aliquots at -80°C and store aliquots of U2 Assay Buffer and ATP at -20°C.
1. Thaw **UBE1, UbCH5b, CBL-B, SRC, TRF Ubiquitin Mix, U2 Assay Buffer, and ATP** on ice. Briefly spin the tubes to recover their full content.

Note: UBE1, UBCH5b, CBL-B, SRC, TRF Ubiquitin Mix, and U2 Assay Buffer are sensitive to freeze/thaw cycles. Avoid multiple freeze-thaw cycles.

2. Prepare a 5x Ubiquitin Mix in U2 Assay Buffer by making a 40-fold dilution of Ubiquitin Mix (200x).
3. Calculate the amount of protein required for the assay and prepare the appropriate amounts of diluted proteins. The concentration of each protein is lot-specific and is indicated on the tube. Verify the initial concentration and dilute accordingly.
 - a) Dilute UBE1 in U2 Assay Buffer to 96 ng/μl (800 nM - the final concentration in the reaction will be 40 nM) (1 μl/well).
 - b) Dilute UbCH5b in U2 Assay Buffer to 144 ng/μl (8 μM – the final concentration in the reaction will be 400 nM) (1 μl/well).
 - c) Dilute CBL-B in U2 Assay Buffer to 7.2 ng/μl (100 nM – the final concentration in the reaction will be 12.5 nM) (2.5 μl/well).
 - d) Dilute SRC in U2 Assay Buffer to 12 ng/μl (200 nM – the final concentration in the reaction will be 25 nM) (2.5 μl/well).

Note: Keep all diluted proteins on ice until use. Do not freeze and re-use diluted proteins.

4. Prepare the Test Inhibitor (4 μl/well): for a titration prepare serial dilutions at concentrations 5-fold higher than the desired final concentrations. The final volume of the reaction is 20 μl.
 - a) If the Test Inhibitor is water-soluble, prepare serial dilutions in the U2 Assay Buffer, 5-fold more concentrated than the desired final concentrations. For the positive and negative controls, use U2 Assay Buffer (Diluent Solution).

OR

- b) If the Test inhibitor is soluble in DMSO, prepare the test inhibitor in 100% DMSO at a concentration 100-fold higher than the highest desired concentration, then dilute the inhibitor 20-fold in U2 Assay

Buffer to prepare the highest concentration of the 5-fold intermediate dilutions. The concentration of DMSO is now 5%.

Prepare serial dilutions of the Test Inhibitor at 5-fold the desired final concentrations using 5% DMSO in U2 Assay Buffer to keep the concentration of DMSO constant.

For positive and negative controls, prepare 5% DMSO in U2 Assay Buffer (vol/vol) so that all wells contain the same amount of DMSO (Diluent Solution).

Note: The final concentration of DMSO should not exceed 1%.

- For the “Blank” wells prepare the following mix: N wells x (4 µl of 5x TRF Ubiquitin Mix + 1 µl of diluted UBE1 + 1 µl of diluted UbcH5b + 4 µl of Diluent Solution + 5 µl of U2 Assay Buffer + 5 µl of ATP (4 mM)).
- Add 20 µl of mix to each “Blank” well.

	Blank
5x TRF Ubiquitin Mix	4 µl
Diluted UBE1	1 µl
Diluted UbcH5b	1 µl
Diluted CBL-B/SRC	-
Test Compound	-
Diluent Solution	4 µl
U2 Assay Buffer	5 µl
ATP (4 mM)	5 µl
Total	20 µl

- Prepare a Master Mix: N wells x (4 µl of 5x TRF Ubiquitin Mix + 1 µl of diluted UBE1 + 1 µl of diluted UbcH5b + 2.5 µl of diluted CBL-B + 2.5 µl of diluted SRC).
- Add 11 µl of Master Mix to each well designated “Negative Control”, “Positive Control” and “Test Inhibitor”.
- Add 4 µl of Test inhibitor to each well designated “Test Inhibitor”.
- Add 4 µl of Diluent Solution to the “Positive Control” and “Negative Control” wells.
- Initiate the reaction by adding 5 µl of **ATP** to the wells labeled “Positive Control” and “Test Inhibitor”.
- Add 5 µl of **U2 Assay Buffer** to the well designated “Negative Control”.

	Test Inhibitor	Negative Control	Positive Control
Master Mix	11 μ l	11 μ l	11 μ l
Test Inhibitor	4 μ l	–	–
Diluent Solution	–	4 μ l	4 μ l
U2 Assay Buffer	–	5 μ l	–
ATP (4 mM)	5 μ l	–	5 μ l
Total	20 μl	20 μl	20 μl

13. Read the fluorescence intensity in a microtiter-plate reader capable of measuring TR-FRET in kinetic mode for up to 1 hour. An end point readout can be done in 20-40min.

14. “Blank” value should be subtracted from all other values.

Instrument Settings

Two sequential measurements should be conducted. Eu-donor emission should be measured at 620 nm followed by dye-acceptor emission at 665 nm. Data analysis is performed using the TR-FRET ratio (665 nm emission/620 nm emission).

Reading Mode	Time Resolved
Excitation Wavelength	317 \pm 20 nm
Emission Wavelength	620 \pm 10 nm
Lag Time	60 μ s
Integration Time	500 μ s
Excitation Wavelength	317 \pm 20 nm
Emission Wavelength	665 \pm 10 nm
Lag Time	60 μ s
Integration Time	500 μ s

Calculating Results

Data analysis is performed using the TR-FRET ratio (665 nm emission/620 nm emission). “Blank” value is subtracted from all other values.

When percentage activity is calculated, the FRET value from the Blank (it is expected that Blank and Negative Control have a similar value) can be set as zero percent activity and the FRET value from the positive control can be set as one hundred percent activity.

$$\% \text{ Activity} = \frac{\text{FRET}_s - \text{FRET}_{\text{blank}}}{\text{FRET}_p - \text{FRET}_{\text{blank}}} \times 100\%$$

Where FRET_s = Sample FRET, FRET_{blank} = Blank FRET, and FRET_p = Positive control FRET.

Example Results




Figure 2: Inhibition of CBL-B-driven SRC ubiquitination by CBL-B-IN-1 and Methylated Ubiquitin. CBL-B-dependent ubiquitination of SRC was measured in the presence of increasing concentrations of methylated Ubiquitin or CBL-B-IN-1 inhibitor (MedChem Express #HY-136339). Results are expressed as percent activity, in which absence of inhibitor is set to 100%.

Data shown is representative. For lot-specific information, please contact BPS Bioscience, Inc. at support@bpsbioscience.com.

Troubleshooting Guide

Visit bpsbioscience.com/assay-kits-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com

Related Products

<i>Products</i>	<i>Catalog #</i>	<i>Size</i>
ChoosE3-Freedom™ Intrachain TR-FRET Assay Kit	78560	384 reactions
ChoosE2-Opti™ Intrachain TR-FRET Assay Kit	78561	384 reactions
CBL-B-driven Tyro3 Ubiquitination Intrachain TR-FRET Assay Kit	78388	384 reactions
C-CBL-driven Tyro3 Ubiquitination Intrachain TR-FRET Assay Kit	78408	384 reactions
CBL-B-driven Axl Ubiquitination Intrachain TR-FRET Assay Kit	78821	384 reactions
C-CBL-driven Axl Ubiquitination Intrachain TR-FRET Assay Kit	78823	384 reactions
CBL-B-driven SRC Ubiquitination Intrachain TR-FRET Assay Kit	78820	384 reactions
C-CBL-driven SRC Ubiquitination Intrachain TR-FRET Assay Kit	78822	384 reactions